Anti-IL23A Monoclonal Antibody for Research & Clinical Applications

Revolutionizing the field of immunology, the anti-IL23A monoclonal antibody by Alpha Lifetech Incorporation is designed to target and neutralize the interleukin-23A (IL-23A) cytokine. This innovative antibody plays a pivotal role in modulating immune responses, making it a valuable tool for researchers investigating various inflammatory and autoimmune conditions, With high specificity and affinity for IL-23A, this monoclonal antibody enables enhanced understanding of IL-23A's involvement in disease mechanisms. Whether used in in-vitro studies or preclinical research, it opens new avenues for therapeutic development aimed at conditions such as psoriasis, Crohn’s disease, and other IL-23A-related disorders, Alpha Lifetech's commitment to quality and precision ensures that this product meets rigorous standards, providing researchers with reliable results. Embrace the potential of targeted immune modulation with the anti-IL23A monoclonal antibody and take strides toward unraveling the complexities of immune system responses

Hot Selling Product

ADT1744-Human Anti-VEGFAxANGPT2 Bispecific Antibody

ADT1752-Human Anti-CD3xCEACAM5 Bispecific Antibody

ADT1753-Human Anti-CD3xGPRC5D Bispecific Antibody

ADT1754-Human Anti-CD3xClaudin18.2 Bispecific Antibody

ADT1755-Human Anti-CTLA4xLAG3 Bispecific Antibody

ADT1758-Human Anti-PD-1xCTLA-4 Bispecific Antibody

Best Chinese anti-IL23A monoclonal antibody Custom Solutions, Ahead of the Curve

In today's fast-evolving biotechnology landscape, Alpha Lifetech Inc. stands out with its exceptional expertise in the production of monoclonal antibodies, particularly the Chinese anti-IL23A monoclonal antibody. Our team, composed of seasoned scientists with extensive backgrounds in membrane protein production and Nanobody discovery, is dedicated to providing cutting-edge custom solutions tailored to meet the unique needs of global buyers. With nearly 10,000 high-quality reagents, cytokines, and drug target antibodies in our product lineup, we position ourselves ahead of the curve in delivering innovative biotechnological solutions. Our anti-IL23A monoclonal antibodies are specifically designed to target Interleukin 23A, a vital cytokine involved in inflammatory responses and various diseases. By offering custom solutions, we allow researchers and pharmaceutical companies to effectively study and manipulate immune pathways, facilitating advancements in therapeutic developments. At Alpha Lifetech, we understand that your research demands precision and reliability; thus, our products undergo rigorous quality control to ensure optimal performance in diverse applications. Partner with us and leverage our expertise to enhance your research capabilities and drive your scientific innovations forward.

Best Chinese anti-IL23A Monoclonal Antibody Custom Solutions, Ahead of the Curve

Product Name	Clonality	Target	Application	Conjugate	Isotype	Quantity (mg)
Anti-IL23A mAb 1	Monoclonal	IL23A	WB, ELISA	Unconjugated	IgG1	1
Anti-IL23A mAb 2	Monoclonal	IL23A	IF, IP	FITC	IgG2a	0.5
Anti-IL23A mAb 3	Monoclonal	IL23A	ELISA	HRP	IgG1	2
Anti-IL23A mAb 4	Monoclonal	IL23A	WB, IHC	AP	IgG2b	1.5

Trends in Monoclonal Antibody Development for IL23A Targeting

The development of monoclonal antibodies targeting IL23A has seen a significant upward trend from 2018 to 2023. This data visualization illustrates the annual increase in the number of monoclonal antibodies developed specifically for targeting IL23A, indicating a growing focus on this therapeutic area within immunology. From a mere three monoclonal antibodies in 2018, the figures have surged to twenty by 2023, reflecting advancements in biopharmaceutical research and an enhanced understanding of IL23A's role in various immune-related conditions. The consistent growth rate illustrates the market's response to the increasing incidence of diseases associated with IL23A dysregulation, such as psoriasis and inflammatory bowel diseases. As research progresses, it is anticipated that more innovative therapies will emerge, further contributing to the expanding landscape of monoclonal antibody treatments. This trend not only underscores the relevance of IL23A in contemporary medicine but also highlights the potential for custom solutions aimed at optimizing patient outcomes in immunological disorders.